Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006.
about
Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.Coronary Artery Bypass Grafting vs. Drug-Eluting Stent Implantation for Multivessel Disease in Patients with Chronic Kidney Disease.The disutility of restenosis--the impact of repeat percutaneous coronary intervention on quality of life.Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up.Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic RegistriesAdequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention.Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.The safety of drug-eluting stents.Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.Coronary stent thrombosis in patients with chronic renal insufficiency.Stenting versus bypass surgery for the treatment of left main coronary artery disease.Nanotechnology and its relationship to interventional radiology. Part II: Drug Delivery, Thermotherapy, and Vascular Intervention.Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.Coronary stents: historical development, current status and future directions.Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis.Intravascular Ultrasound Analysis of Intraplaque Versus Subintimal Tracking in Percutaneous Intervention for Coronary Chronic Total Occlusions and Association With Procedural Outcomes.Long-term outcomes following mini-crush versus culotte stenting for the treatment of unprotected left main disease: Insights from the milan and New-Tokyo (MITO) registry.Clinical Outcomes Following Covered Stent for the Treatment of Coronary Artery Perforation.Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy.Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients.Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy.The outcomes of intravascular ultrasound-guided drug-eluting stent implantation among patients with complex coronary lesions: a comprehensive meta-analysis of 15 clinical trials and 8,084 patients.Long-term clinical outcomes of successful versus unsuccessful revascularization with drug-eluting stents for true chronic total occlusion.Long-term clinical outcomes of the one-stent technique versus the two-stent technique for non-left main true coronary bifurcation disease in the era of drug-eluting stents.Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound.The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: the Milan and New-Tokyo (MITO) Registry.Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience.Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation.Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.Meta-analysis and systematic review of intravascular ultrasound versus angiography-guided drug eluting stent implantation in left main coronary disease in 4592 patients.Perspectives on the Emerging Applications of Multifaceted Biomedical Polymeric Nanomaterials
P2860
Q33642414-6649B2DD-B34F-4D7F-8B53-A1E676910C44Q33740804-F148775C-DC0C-4EC0-A268-6A49A0F889D6Q33994074-0E85FE2E-DF66-45F6-A070-C9227386260CQ34319885-255F22B2-17FF-4E9A-9988-37C310D4389AQ34505408-A38BE5A9-DB24-41B8-947C-32D3111E649AQ35575189-45B3803D-900D-4F63-8C87-9FD1EDC33F8EQ35830571-1FDAC6D9-6AC8-45FF-B61F-17B9CC6E00F9Q35878281-45155DE8-7B0F-4094-A9AD-5E80DED27707Q36624476-927EC8F0-C79C-4ED2-8E04-2CAA4604959CQ37089062-D4AC90E1-4CA3-4F5C-9F49-F4F74BEDFFF1Q37362714-33A44622-DC32-409F-8BA5-D2A9449BD143Q37387506-5DAC9ABD-6F67-404D-AB88-27A95D964BF6Q37582058-B2F43EAD-BA90-4A83-8614-1E3FEC108F6EQ37666555-ED01DF90-0BE2-4438-B881-45763B274CEAQ37789181-1B1FEDB8-C209-429B-A15B-788117D216FCQ37997017-EE198B11-0671-49F1-A210-7C003DC13F04Q38023285-5A767458-04A4-4498-862A-BC0C0DB7F4B2Q38029478-6094C122-90B9-4814-9B92-6FE1A7B274E3Q38093501-EBE7CF1F-7D39-4FB5-BDC8-BF8F727B6B36Q38265442-8B5950B7-69EC-4F0F-8B73-A614C5350192Q38776391-7CC48718-95A8-455D-B953-815C6178EFE0Q39547065-2A98F5AC-9236-464E-8E19-BD184F2B1CA5Q40515000-025411D7-586B-42D8-A729-B70D05A958C7Q40899680-5B0BA3D8-1F57-495B-A494-75B726A11DE0Q41016271-48AA7263-74F7-49C4-8291-645A423F358DQ41551745-13F0FE26-15FA-47D3-8BA2-D319A4CBCD86Q42003024-E59644B1-B145-4DFB-94B1-E2C346FB5416Q42078083-4570D5A3-6050-4BBE-92E3-089A55D34A11Q43525993-CC86C414-A32F-4F3F-9636-3E74AE30DFCFQ45731822-645AEB15-1C8D-4AD3-839B-2D69E7DFED1DQ47253711-870339AC-A1FE-4457-9AF4-82348AF9AF08Q50096658-8446D3AA-E4C0-40B9-B60B-1672C8C182ECQ51190742-4070B25B-B739-442E-AC20-AD35FF8A0D6DQ51784255-CAC69945-4CCA-464A-A3D0-DFC858A45395Q53074100-F54E02AA-6B05-421E-9EAF-520DE9EABB5AQ53311332-E37A6A3C-7182-4D05-AFAF-84ED98EA79CBQ53384415-83AB6475-9FA5-4B0F-AE7B-6664DB286DEBQ55414293-4581757C-2FE9-4FCE-BDB8-644579125175Q59113204-E361F131-7E45-43CF-929B-01BC235CC837
P2860
Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@en
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@nl
type
label
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@en
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@nl
prefLabel
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@en
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@nl
P1433
P1476
Thrombosis in coronary drug-el ...... ic Health, December 7-8, 2006.
@en
P2093
Warren K Laskey
William H Maisel
P304
P356
10.1161/CIRCULATIONAHA.107.688416
P407
P50
P577
2007-05-01T00:00:00Z